Exclusive Summary

• - Core patents of originator Fusilev have expired; multiple generics have launched globally since 2018, making it a mature generic market.
• - 5-FU–based regimens in colorectal cancer cover roughly 1.1–1.5 million patients/year worldwide, with about 10–24 vials per patient per treatment course.
• - Major guidelines (e.g., NCCN, ESMO) accept levoleucovorin as equivalent to leucovorin (1:2 conversion) for both HD-MTX rescue and standard 5-FU regimens (FOLFOX/FOLFIRI).
• - US registration and ready-to-use high-strength injections (175 mg/17.5 mL, 250 mg/25 mL) provide strong quality credentials and pharmacy workflow advantages.
• - As a generic, it can be priced substantially below the brand (often >60% lower), enabling competitiveness in tenders and emerging markets with reliable supply.